195 Cutaneous toxicities associated with immune checkpoint inhibitors: An observational, pharmacovigilance study

Cutaneous immune-related adverse events (cirAEs) are the most prevalent complication to arise from immunotherapy. We determined the spectrum, timing, clinical features, and outcomes of cirAEs by conducting an observational pharmacovigilance study (ClinicalTrials.gov, NCT04898751) employing Vigibase, the WHO’s global database of individual case safety reports. Using a Bayesian confidence propagation neural network method, cutaneous toxicities were identified with a positive signal at the bottom of the information component 95% confidence interval (IC025 >0).